Recombinant protein · Inhibitor of SNAP-25 · developed by Allergan
Onabotulinumtoxina (BOTOX) is a botulinum neurotoxin type A that enters nerve terminals and cleaves SNAP-25, blocking acetylcholine release and causing localized partial chemical denervation of muscle or reduced sweat gland activity. It is used in neurologic, urologic, musculoskeletal, ophthalmic and cosmetic indications involving muscle overactivity or excess sweating.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 2, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06068855 | Phase 3 | Masseter Muscle Prominence | Completed | ABBV |
| NCT07871513 | Phase 2 | Upper Facial Lines | Recruiting | ABBV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glabellar LinesUpper Facial Lines
Updated Nov 8, 2026. Something wrong or missing? Report it on the ABBV page.
See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABBV catalysts and pipeline →